PI3K/AKT/mTOR Pathway in ATLL: from Basic Biology to Preclinical Study
Received Date: Nov 26, 2018 / Accepted Date: Feb 12, 2019 / Published Date: Feb 18, 2019
Abstract
Adult T-cell leukemia/ lymphoma (ATLL) is high resistance fatal malignancy which has a poor prognosis and exhibits resistance to conventional chemotherapy. The development of novel therapies for ATLL relies on a comprehensive understanding of the occurrences that result in cellular survival and proliferation regulating pathways that control growth signals is an emerging and complementary approach to ATL treatment. The PI3K/AKT/mTOR is a pivotal gatekeeper for cell growth, viability, migration, proliferation, and development drug resistance. Activation of PI3K, AKT, mTOR regulates important genes and proteins like mTOR, p53, NF-κB, P27, P21, S6K, FKHR and BAD. So this rout has a central role in handling cell cycle regulators, transcription factors and anti-apoptotic proteins. This review focuses on the role of PI3K/AKT/mTOR in ATL progression and development drug resistance.
Keywords: PI3K; AKT; mTOR; HTLV-1; ATLL
Citation: Naghinezhad J (2019) PI3K/AKT/mTOR Pathway in ATLL: from Basic Biology to Preclinical Study. J Cell Mol Pharmacol 3: 104.
Copyright: © 2019 Naghinezhad J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 4025
- [From(publication date): 0-2019 - Nov 19, 2024]
- Breakdown by view type
- HTML page views: 3303
- PDF downloads: 722
